Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 16k
9 October 2018
Question for written answer E-005147-18
to the Commission
Rule 130
Mario Borghezio (ENF) , Danilo Oscar Lancini (ENF)

 Subject:  European Medicines Agency
 Answer in writing 

In a press release, the European Medicines Agency (EMA) reports that the Agency will lose more staff than was initially anticipated, either because not all the current members of staff will transfer to Amsterdam and will therefore leave the EMA, or because of employment regulations in force in the Netherlands concerning short-term contracts.

The Agency estimates that it will lose around 30% of its staff, with a high degree of uncertainty regarding midterm staff retention.

The EMA will have to reorganise to be able to carry out its core activities, and will scale back its secondary activities for a while. It will not undertake any new tasks in 2019 and will also scale back its collaboration at international level next year.

Its reduced operational capacity will have a direct impact on approval of medicines for long periods of time. The likely negative repercussions of this will hit both public health and the pharmaceutical market.

1. In view of the above, does the Commission still consider as valid the assessment made prior to the relocation decision?

2. Is it considering reopening the award procedure?

Original language of question: IT 
Last updated: 24 October 2018Legal notice - Privacy policy